nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—acquired immunodeficiency syndrome	0.245	1	CbGaD
Naloxone—SLCO1A2—Indinavir—acquired immunodeficiency syndrome	0.0511	0.0962	CbGbCtD
Naloxone—SLCO1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0496	0.0933	CbGbCtD
Naloxone—SLCO1A2—Ritonavir—acquired immunodeficiency syndrome	0.0449	0.0844	CbGbCtD
Naloxone—SLCO1A2—Saquinavir—acquired immunodeficiency syndrome	0.0449	0.0844	CbGbCtD
Naloxone—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0236	0.0445	CbGbCtD
Naloxone—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0236	0.0445	CbGbCtD
Naloxone—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0232	0.0436	CbGbCtD
Naloxone—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0222	0.0418	CbGbCtD
Naloxone—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0179	0.0337	CbGbCtD
Naloxone—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0179	0.0337	CbGbCtD
Naloxone—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0177	0.0333	CbGbCtD
Naloxone—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0172	0.0323	CbGbCtD
Naloxone—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.016	0.0301	CbGbCtD
Naloxone—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0138	0.026	CbGbCtD
Naloxone—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0134	0.0252	CbGbCtD
Naloxone—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0121	0.0228	CbGbCtD
Naloxone—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0121	0.0228	CbGbCtD
Naloxone—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0116	0.0219	CbGbCtD
Naloxone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0113	0.0212	CbGbCtD
Naloxone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0106	0.0199	CbGbCtD
Naloxone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0106	0.0199	CbGbCtD
Naloxone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00959	0.018	CbGbCtD
Naloxone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00959	0.018	CbGbCtD
Naloxone—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.009	0.0169	CbGbCtD
Naloxone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00828	0.0156	CbGbCtD
Naloxone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00804	0.0151	CbGbCtD
Naloxone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00727	0.0137	CbGbCtD
Naloxone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00727	0.0137	CbGbCtD
Naloxone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00697	0.0131	CbGbCtD
Naloxone—CREB1—nerve—acquired immunodeficiency syndrome	0.00415	0.0769	CbGeAlD
Naloxone—CREB1—blood plasma—acquired immunodeficiency syndrome	0.00314	0.0582	CbGeAlD
Naloxone—TLR4—blood—acquired immunodeficiency syndrome	0.00261	0.0484	CbGeAlD
Naloxone—TLR4—bone marrow—acquired immunodeficiency syndrome	0.00253	0.0469	CbGeAlD
Naloxone—CREB1—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	0.00239	1	CbGdCrCtD
Naloxone—TLR4—lung—acquired immunodeficiency syndrome	0.00229	0.0425	CbGeAlD
Naloxone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00224	0.0415	CbGeAlD
Naloxone—CREB1—retina—acquired immunodeficiency syndrome	0.00172	0.0319	CbGeAlD
Naloxone—TLR4—brain—acquired immunodeficiency syndrome	0.00162	0.03	CbGeAlD
Naloxone—TLR4—lymph node—acquired immunodeficiency syndrome	0.00157	0.029	CbGeAlD
Naloxone—CREB1—skin of body—acquired immunodeficiency syndrome	0.00151	0.028	CbGeAlD
Naloxone—CREB1—lymphoid tissue—acquired immunodeficiency syndrome	0.00122	0.0227	CbGeAlD
Naloxone—CREB1—digestive system—acquired immunodeficiency syndrome	0.00121	0.0224	CbGeAlD
Naloxone—CREB1—blood—acquired immunodeficiency syndrome	0.00115	0.0213	CbGeAlD
Naloxone—CREB1—bone marrow—acquired immunodeficiency syndrome	0.00111	0.0206	CbGeAlD
Naloxone—CREB1—spinal cord—acquired immunodeficiency syndrome	0.00111	0.0205	CbGeAlD
Naloxone—CREB1—vagina—acquired immunodeficiency syndrome	0.00107	0.0198	CbGeAlD
Naloxone—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00102	0.0189	CbGeAlD
Naloxone—CREB1—lung—acquired immunodeficiency syndrome	0.00101	0.0187	CbGeAlD
Naloxone—CREB1—nervous system—acquired immunodeficiency syndrome	0.000933	0.0173	CbGeAlD
Naloxone—CREB1—central nervous system—acquired immunodeficiency syndrome	0.000899	0.0167	CbGeAlD
Naloxone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000738	0.0137	CbGeAlD
Naloxone—CREB1—brain—acquired immunodeficiency syndrome	0.000713	0.0132	CbGeAlD
Naloxone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00071	0.0132	CbGeAlD
Naloxone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000707	0.0131	CbGeAlD
Naloxone—CREB1—lymph node—acquired immunodeficiency syndrome	0.000689	0.0128	CbGeAlD
Naloxone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000689	0.0128	CbGeAlD
Naloxone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000681	0.0126	CbGeAlD
Naloxone—OPRM1—blood—acquired immunodeficiency syndrome	0.00062	0.0115	CbGeAlD
Naloxone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000597	0.0111	CbGeAlD
Naloxone—Hot flush—Saquinavir—acquired immunodeficiency syndrome	0.000567	0.00537	CcSEcCtD
Naloxone—OPRD1—brain—acquired immunodeficiency syndrome	0.000564	0.0105	CbGeAlD
Naloxone—Menopausal symptoms—Saquinavir—acquired immunodeficiency syndrome	0.000562	0.00533	CcSEcCtD
Naloxone—SLCO1A2—digestive system—acquired immunodeficiency syndrome	0.00056	0.0104	CbGeAlD
Naloxone—Nasopharyngitis—Efavirenz—acquired immunodeficiency syndrome	0.000557	0.00528	CcSEcCtD
Naloxone—OPRK1—brain—acquired immunodeficiency syndrome	0.000541	0.01	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.000525	0.00497	CcSEcCtD
Naloxone—Sweating—Zidovudine—acquired immunodeficiency syndrome	0.000524	0.00496	CcSEcCtD
Naloxone—SLCO1A2—spinal cord—acquired immunodeficiency syndrome	0.000514	0.00953	CbGeAlD
Naloxone—Angiopathy—Nelfinavir—acquired immunodeficiency syndrome	0.000513	0.00487	CcSEcCtD
Naloxone—Irritability—Saquinavir—acquired immunodeficiency syndrome	0.000506	0.0048	CcSEcCtD
Naloxone—Chills—Stavudine—acquired immunodeficiency syndrome	0.000506	0.0048	CcSEcCtD
Naloxone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000503	0.00933	CbGeAlD
Naloxone—Chills—Abacavir—acquired immunodeficiency syndrome	0.000499	0.00473	CcSEcCtD
Naloxone—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.000497	0.00471	CcSEcCtD
Naloxone—Mental disorder—Stavudine—acquired immunodeficiency syndrome	0.000494	0.00468	CcSEcCtD
Naloxone—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.000492	0.00466	CcSEcCtD
Naloxone—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000488	0.00905	CbGeAlD
Naloxone—Sweating—Indinavir—acquired immunodeficiency syndrome	0.000487	0.00461	CcSEcCtD
Naloxone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000484	0.00898	CbGeAlD
Naloxone—ESR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000481	0.00892	CbGeAlD
Naloxone—Depression—Efavirenz—acquired immunodeficiency syndrome	0.000479	0.00454	CcSEcCtD
Naloxone—ESR1—digestive system—acquired immunodeficiency syndrome	0.000475	0.00881	CbGeAlD
Naloxone—SLCO1A2—lung—acquired immunodeficiency syndrome	0.000468	0.00867	CbGeAlD
Naloxone—Sweating—Efavirenz—acquired immunodeficiency syndrome	0.00046	0.00436	CcSEcCtD
Naloxone—Cardiac disorder—Zidovudine—acquired immunodeficiency syndrome	0.000455	0.00431	CcSEcCtD
Naloxone—Paraesthesia—Amprenavir—acquired immunodeficiency syndrome	0.000455	0.00431	CcSEcCtD
Naloxone—Agitation—Nelfinavir—acquired immunodeficiency syndrome	0.000453	0.00429	CcSEcCtD
Naloxone—ESR1—blood—acquired immunodeficiency syndrome	0.000453	0.00839	CbGeAlD
Naloxone—Nasopharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.000452	0.00429	CcSEcCtD
Naloxone—Mediastinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000442	0.00419	CcSEcCtD
Naloxone—Chills—Zidovudine—acquired immunodeficiency syndrome	0.00044	0.00417	CcSEcCtD
Naloxone—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.000437	0.00414	CcSEcCtD
Naloxone—SLCO1A2—nervous system—acquired immunodeficiency syndrome	0.000433	0.00803	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00043	0.00408	CcSEcCtD
Naloxone—Mental disorder—Zidovudine—acquired immunodeficiency syndrome	0.00043	0.00407	CcSEcCtD
Naloxone—Hallucination—Efavirenz—acquired immunodeficiency syndrome	0.000429	0.00406	CcSEcCtD
Naloxone—Convulsion—Nelfinavir—acquired immunodeficiency syndrome	0.000427	0.00404	CcSEcCtD
Naloxone—Depression—Ritonavir—acquired immunodeficiency syndrome	0.000423	0.00401	CcSEcCtD
Naloxone—Flushing—Indinavir—acquired immunodeficiency syndrome	0.000423	0.00401	CcSEcCtD
Naloxone—ESR1—vagina—acquired immunodeficiency syndrome	0.00042	0.00778	CbGeAlD
Naloxone—Convulsion—Abacavir—acquired immunodeficiency syndrome	0.000419	0.00397	CcSEcCtD
Naloxone—Tension—Zidovudine—acquired immunodeficiency syndrome	0.000419	0.00397	CcSEcCtD
Naloxone—SLCO1A2—central nervous system—acquired immunodeficiency syndrome	0.000417	0.00773	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.000417	0.00395	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.000415	0.00393	CcSEcCtD
Naloxone—Nervousness—Zidovudine—acquired immunodeficiency syndrome	0.000415	0.00393	CcSEcCtD
Naloxone—Paraesthesia—Didanosine—acquired immunodeficiency syndrome	0.000415	0.00393	CcSEcCtD
Naloxone—Hallucination—Delavirdine—acquired immunodeficiency syndrome	0.00041	0.00389	CcSEcCtD
Naloxone—Chills—Indinavir—acquired immunodeficiency syndrome	0.000409	0.00388	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.000409	0.00388	CcSEcCtD
Naloxone—Depression—Saquinavir—acquired immunodeficiency syndrome	0.000408	0.00386	CcSEcCtD
Naloxone—Sweating—Ritonavir—acquired immunodeficiency syndrome	0.000407	0.00386	CcSEcCtD
Naloxone—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.000407	0.00386	CcSEcCtD
Naloxone—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.000403	0.00382	CcSEcCtD
Naloxone—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.0004	0.00379	CcSEcCtD
Naloxone—Tremor—Zidovudine—acquired immunodeficiency syndrome	0.0004	0.00379	CcSEcCtD
Naloxone—Flushing—Efavirenz—acquired immunodeficiency syndrome	0.0004	0.00379	CcSEcCtD
Naloxone—Cardiac disorder—Efavirenz—acquired immunodeficiency syndrome	0.0004	0.00379	CcSEcCtD
Naloxone—ESR1—lung—acquired immunodeficiency syndrome	0.000397	0.00736	CbGeAlD
Naloxone—Pain—Didanosine—acquired immunodeficiency syndrome	0.000395	0.00374	CcSEcCtD
Naloxone—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.000393	0.00372	CcSEcCtD
Naloxone—Angiopathy—Efavirenz—acquired immunodeficiency syndrome	0.000391	0.0037	CcSEcCtD
Naloxone—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000391	0.0037	CcSEcCtD
Naloxone—Tension—Indinavir—acquired immunodeficiency syndrome	0.00039	0.00369	CcSEcCtD
Naloxone—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.000389	0.00369	CcSEcCtD
Naloxone—Depression—Lamivudine—acquired immunodeficiency syndrome	0.000389	0.00368	CcSEcCtD
Naloxone—Hyperhidrosis—Nelfinavir—acquired immunodeficiency syndrome	0.000389	0.00368	CcSEcCtD
Naloxone—Mediastinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000388	0.00368	CcSEcCtD
Naloxone—Hyperhidrosis—Stavudine—acquired immunodeficiency syndrome	0.000388	0.00367	CcSEcCtD
Naloxone—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.000387	0.00367	CcSEcCtD
Naloxone—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.000386	0.00365	CcSEcCtD
Naloxone—OPRM1—brain—acquired immunodeficiency syndrome	0.000385	0.00713	CbGeAlD
Naloxone—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000384	0.00363	CcSEcCtD
Naloxone—Hallucination—Ritonavir—acquired immunodeficiency syndrome	0.000379	0.00359	CcSEcCtD
Naloxone—Sweating—Lamivudine—acquired immunodeficiency syndrome	0.000374	0.00354	CcSEcCtD
Naloxone—CYP2C8—blood—acquired immunodeficiency syndrome	0.000373	0.00691	CbGeAlD
Naloxone—Paraesthesia—Nevirapine—acquired immunodeficiency syndrome	0.000373	0.00353	CcSEcCtD
Naloxone—Tremor—Indinavir—acquired immunodeficiency syndrome	0.000372	0.00352	CcSEcCtD
Naloxone—Chills—Delavirdine—acquired immunodeficiency syndrome	0.00037	0.00351	CcSEcCtD
Naloxone—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.00037	0.0035	CcSEcCtD
Naloxone—Tension—Efavirenz—acquired immunodeficiency syndrome	0.000368	0.00349	CcSEcCtD
Naloxone—ESR1—nervous system—acquired immunodeficiency syndrome	0.000367	0.00681	CbGeAlD
Naloxone—Hallucination—Saquinavir—acquired immunodeficiency syndrome	0.000365	0.00346	CcSEcCtD
Naloxone—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000365	0.00346	CcSEcCtD
Naloxone—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.000365	0.00346	CcSEcCtD
Naloxone—Agitation—Indinavir—acquired immunodeficiency syndrome	0.000365	0.00346	CcSEcCtD
Naloxone—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.000364	0.00345	CcSEcCtD
Naloxone—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000363	0.00344	CcSEcCtD
Naloxone—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.000361	0.00342	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000361	0.00342	CcSEcCtD
Naloxone—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00036	0.00341	CcSEcCtD
Naloxone—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.000358	0.0034	CcSEcCtD
Naloxone—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000358	0.0034	CcSEcCtD
Naloxone—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000355	0.00336	CcSEcCtD
Naloxone—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.000355	0.00336	CcSEcCtD
Naloxone—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000354	0.00335	CcSEcCtD
Naloxone—Flushing—Ritonavir—acquired immunodeficiency syndrome	0.000354	0.00335	CcSEcCtD
Naloxone—ESR1—central nervous system—acquired immunodeficiency syndrome	0.000354	0.00656	CbGeAlD
Naloxone—Tension—Delavirdine—acquired immunodeficiency syndrome	0.000352	0.00334	CcSEcCtD
Naloxone—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.000352	0.00334	CcSEcCtD
Naloxone—Tremor—Efavirenz—acquired immunodeficiency syndrome	0.000351	0.00333	CcSEcCtD
Naloxone—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.000349	0.0033	CcSEcCtD
Naloxone—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000347	0.00329	CcSEcCtD
Naloxone—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000347	0.00328	CcSEcCtD
Naloxone—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000346	0.00328	CcSEcCtD
Naloxone—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000346	0.00328	CcSEcCtD
Naloxone—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000346	0.00641	CbGeAlD
Naloxone—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.000345	0.00327	CcSEcCtD
Naloxone—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000344	0.00326	CcSEcCtD
Naloxone—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000344	0.00326	CcSEcCtD
Naloxone—Pain—Stavudine—acquired immunodeficiency syndrome	0.000343	0.00325	CcSEcCtD
Naloxone—Chills—Ritonavir—acquired immunodeficiency syndrome	0.000342	0.00324	CcSEcCtD
Naloxone—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000342	0.00324	CcSEcCtD
Naloxone—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000341	0.00323	CcSEcCtD
Naloxone—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000341	0.00323	CcSEcCtD
Naloxone—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000338	0.00321	CcSEcCtD
Naloxone—Pain—Abacavir—acquired immunodeficiency syndrome	0.000338	0.0032	CcSEcCtD
Naloxone—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000337	0.00319	CcSEcCtD
Naloxone—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.000336	0.00319	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000336	0.00318	CcSEcCtD
Naloxone—Mental disorder—Ritonavir—acquired immunodeficiency syndrome	0.000334	0.00316	CcSEcCtD
Naloxone—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.000333	0.00315	CcSEcCtD
Naloxone—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000331	0.00314	CcSEcCtD
Naloxone—SLCO1A2—brain—acquired immunodeficiency syndrome	0.000331	0.00614	CbGeAlD
Naloxone—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000331	0.00313	CcSEcCtD
Naloxone—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.00033	0.00313	CcSEcCtD
Naloxone—Chills—Saquinavir—acquired immunodeficiency syndrome	0.000329	0.00312	CcSEcCtD
Naloxone—ALB—brain—acquired immunodeficiency syndrome	0.000329	0.0061	CbGeAlD
Naloxone—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000328	0.00311	CcSEcCtD
Naloxone—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000328	0.00311	CcSEcCtD
Naloxone—Tension—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.00309	CcSEcCtD
Naloxone—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000325	0.00308	CcSEcCtD
Naloxone—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000324	0.00307	CcSEcCtD
Naloxone—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.00305	CcSEcCtD
Naloxone—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000322	0.00305	CcSEcCtD
Naloxone—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000321	0.00305	CcSEcCtD
Naloxone—ALB—lymph node—acquired immunodeficiency syndrome	0.000318	0.0059	CbGeAlD
Naloxone—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000318	0.00301	CcSEcCtD
Naloxone—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000318	0.00301	CcSEcCtD
Naloxone—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000318	0.00301	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000317	0.00301	CcSEcCtD
Naloxone—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000317	0.003	CcSEcCtD
Naloxone—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000317	0.003	CcSEcCtD
Naloxone—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000316	0.00299	CcSEcCtD
Naloxone—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000315	0.00299	CcSEcCtD
Naloxone—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000315	0.00298	CcSEcCtD
Naloxone—Chills—Lamivudine—acquired immunodeficiency syndrome	0.000314	0.00298	CcSEcCtD
Naloxone—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000313	0.00297	CcSEcCtD
Naloxone—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000313	0.00296	CcSEcCtD
Naloxone—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000312	0.00296	CcSEcCtD
Naloxone—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000312	0.00296	CcSEcCtD
Naloxone—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000311	0.00295	CcSEcCtD
Naloxone—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000311	0.00294	CcSEcCtD
Naloxone—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00031	0.00294	CcSEcCtD
Naloxone—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000305	0.00289	CcSEcCtD
Naloxone—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000301	0.00285	CcSEcCtD
Naloxone—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000301	0.00285	CcSEcCtD
Naloxone—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.0003	0.00284	CcSEcCtD
Naloxone—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000299	0.00284	CcSEcCtD
Naloxone—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000299	0.00283	CcSEcCtD
Naloxone—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000299	0.00283	CcSEcCtD
Naloxone—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000298	0.00282	CcSEcCtD
Naloxone—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000298	0.00282	CcSEcCtD
Naloxone—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000297	0.00282	CcSEcCtD
Naloxone—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.0028	CcSEcCtD
Naloxone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000296	0.0028	CcSEcCtD
Naloxone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000294	0.00278	CcSEcCtD
Naloxone—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000294	0.00278	CcSEcCtD
Naloxone—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000291	0.00276	CcSEcCtD
Naloxone—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000289	0.00274	CcSEcCtD
Naloxone—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000288	0.00273	CcSEcCtD
Naloxone—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000288	0.00273	CcSEcCtD
Naloxone—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.00272	CcSEcCtD
Naloxone—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000287	0.00272	CcSEcCtD
Naloxone—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000286	0.00271	CcSEcCtD
Naloxone—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000286	0.00271	CcSEcCtD
Naloxone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000285	0.0027	CcSEcCtD
Naloxone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000284	0.00269	CcSEcCtD
Naloxone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000283	0.00268	CcSEcCtD
Naloxone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000283	0.00268	CcSEcCtD
Naloxone—ESR1—brain—acquired immunodeficiency syndrome	0.000281	0.00521	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000281	0.00266	CcSEcCtD
Naloxone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00028	0.00265	CcSEcCtD
Naloxone—Pain—Indinavir—acquired immunodeficiency syndrome	0.000277	0.00263	CcSEcCtD
Naloxone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.00262	CcSEcCtD
Naloxone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000276	0.00261	CcSEcCtD
Naloxone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000275	0.00261	CcSEcCtD
Naloxone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000275	0.00261	CcSEcCtD
Naloxone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000275	0.00261	CcSEcCtD
Naloxone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.0026	CcSEcCtD
Naloxone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000274	0.0026	CcSEcCtD
Naloxone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000274	0.0026	CcSEcCtD
Naloxone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000273	0.00259	CcSEcCtD
Naloxone—ESR1—lymph node—acquired immunodeficiency syndrome	0.000271	0.00503	CbGeAlD
Naloxone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00027	0.00256	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00027	0.00256	CcSEcCtD
Naloxone—ABCB1—retina—acquired immunodeficiency syndrome	0.000267	0.00495	CbGeAlD
Naloxone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000266	0.00252	CcSEcCtD
Naloxone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000265	0.00491	CbGeAlD
Naloxone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000264	0.0025	CcSEcCtD
Naloxone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000264	0.0025	CcSEcCtD
Naloxone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.0025	CcSEcCtD
Naloxone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000264	0.0025	CcSEcCtD
Naloxone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000263	0.00249	CcSEcCtD
Naloxone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.00249	CcSEcCtD
Naloxone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.00248	CcSEcCtD
Naloxone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000262	0.00248	CcSEcCtD
Naloxone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000261	0.00247	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.00244	CcSEcCtD
Naloxone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000256	0.00243	CcSEcCtD
Naloxone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000256	0.00243	CcSEcCtD
Naloxone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000256	0.00242	CcSEcCtD
Naloxone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000256	0.00242	CcSEcCtD
Naloxone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000255	0.00241	CcSEcCtD
Naloxone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000253	0.0024	CcSEcCtD
Naloxone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.0024	CcSEcCtD
Naloxone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000253	0.00468	CbGeAlD
Naloxone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.00239	CcSEcCtD
Naloxone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000251	0.00238	CcSEcCtD
Naloxone—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00025	0.00237	CcSEcCtD
Naloxone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00025	0.00237	CcSEcCtD
Naloxone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000247	0.00234	CcSEcCtD
Naloxone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.00231	CcSEcCtD
Naloxone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.0023	CcSEcCtD
Naloxone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000242	0.00229	CcSEcCtD
Naloxone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000242	0.00229	CcSEcCtD
Naloxone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000242	0.00229	CcSEcCtD
Naloxone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000241	0.00229	CcSEcCtD
Naloxone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.00228	CcSEcCtD
Naloxone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000239	0.00226	CcSEcCtD
Naloxone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000238	0.00226	CcSEcCtD
Naloxone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000238	0.00226	CcSEcCtD
Naloxone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000235	0.00222	CcSEcCtD
Naloxone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.00222	CcSEcCtD
Naloxone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.00222	CcSEcCtD
Naloxone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000232	0.0022	CcSEcCtD
Naloxone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.0022	CcSEcCtD
Naloxone—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000232	0.00219	CcSEcCtD
Naloxone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000232	0.00219	CcSEcCtD
Naloxone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000232	0.00219	CcSEcCtD
Naloxone—CYP2C8—brain—acquired immunodeficiency syndrome	0.000231	0.00429	CbGeAlD
Naloxone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.00213	CcSEcCtD
Naloxone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.00212	CcSEcCtD
Naloxone—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.00211	CcSEcCtD
Naloxone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.0021	CcSEcCtD
Naloxone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000222	0.0021	CcSEcCtD
Naloxone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000222	0.0021	CcSEcCtD
Naloxone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.00208	CcSEcCtD
Naloxone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.00203	CcSEcCtD
Naloxone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000214	0.00203	CcSEcCtD
Naloxone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000214	0.00203	CcSEcCtD
Naloxone—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000213	0.00202	CcSEcCtD
Naloxone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00021	0.00199	CcSEcCtD
Naloxone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000209	0.00198	CcSEcCtD
Naloxone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000207	0.00196	CcSEcCtD
Naloxone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000206	0.00195	CcSEcCtD
Naloxone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000206	0.00195	CcSEcCtD
Naloxone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000206	0.00195	CcSEcCtD
Naloxone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000205	0.0038	CbGeAlD
Naloxone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.0019	CcSEcCtD
Naloxone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000197	0.00366	CbGeAlD
Naloxone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000197	0.00186	CcSEcCtD
Naloxone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000197	0.00186	CcSEcCtD
Naloxone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.00184	CcSEcCtD
Naloxone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000194	0.00184	CcSEcCtD
Naloxone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000192	0.00182	CcSEcCtD
Naloxone—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.00019	0.00352	CbGeAlD
Naloxone—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000188	0.00348	CbGeAlD
Naloxone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000187	0.00177	CcSEcCtD
Naloxone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.00176	CcSEcCtD
Naloxone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.00176	CcSEcCtD
Naloxone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000182	0.00172	CcSEcCtD
Naloxone—ABCB1—blood—acquired immunodeficiency syndrome	0.000179	0.00331	CbGeAlD
Naloxone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000178	0.00169	CcSEcCtD
Naloxone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.00169	CcSEcCtD
Naloxone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000174	0.00165	CcSEcCtD
Naloxone—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000173	0.00321	CbGeAlD
Naloxone—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000172	0.00319	CbGeAlD
Naloxone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.00163	CcSEcCtD
Naloxone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.00161	CcSEcCtD
Naloxone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.00157	CcSEcCtD
Naloxone—ABCB1—vagina—acquired immunodeficiency syndrome	0.000166	0.00307	CbGeAlD
Naloxone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000161	0.00152	CcSEcCtD
Naloxone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.0015	CcSEcCtD
Naloxone—ABCB1—lung—acquired immunodeficiency syndrome	0.000157	0.00291	CbGeAlD
Naloxone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.00147	CcSEcCtD
Naloxone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.0014	CcSEcCtD
Naloxone—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000145	0.00269	CbGeAlD
Naloxone—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.00014	0.00259	CbGeAlD
Naloxone—ABCB1—brain—acquired immunodeficiency syndrome	0.000111	0.00206	CbGeAlD
Naloxone—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000107	0.00199	CbGeAlD
Naloxone—CREB1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	7.45e-05	0.00121	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.43e-05	0.00121	CbGpPWpGaD
Naloxone—CREB1—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	7.34e-05	0.00119	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.27e-05	0.00118	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.24e-05	0.00118	CbGpPWpGaD
Naloxone—CREB1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	7.21e-05	0.00117	CbGpPWpGaD
Naloxone—CREB1—Disease—CCNT1—acquired immunodeficiency syndrome	7.17e-05	0.00116	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—TAT—acquired immunodeficiency syndrome	7.15e-05	0.00116	CbGpPWpGaD
Naloxone—CREB1—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	7.08e-05	0.00115	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	6.99e-05	0.00114	CbGpPWpGaD
Naloxone—CREB1—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	6.96e-05	0.00113	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.84e-05	0.00111	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.83e-05	0.00111	CbGpPWpGaD
Naloxone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.75e-05	0.0011	CbGpPWpGaD
Naloxone—CREB1—Immune System—ACTG1—acquired immunodeficiency syndrome	6.73e-05	0.00109	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.72e-05	0.00109	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.71e-05	0.00109	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	6.71e-05	0.00109	CbGpPWpGaD
Naloxone—CREB1—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	6.68e-05	0.00108	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.67e-05	0.00108	CbGpPWpGaD
Naloxone—CREB1—Adipogenesis—TNF—acquired immunodeficiency syndrome	6.65e-05	0.00108	CbGpPWpGaD
Naloxone—ESR1—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	6.62e-05	0.00107	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.6e-05	0.00107	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.43e-05	0.00104	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.43e-05	0.00104	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.42e-05	0.00104	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.28e-05	0.00102	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	6.25e-05	0.00101	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	6.22e-05	0.00101	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.12e-05	0.000993	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	6.08e-05	0.000987	CbGpPWpGaD
Naloxone—CREB1—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	6.01e-05	0.000975	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.94e-05	0.000964	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.78e-05	0.000939	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.78e-05	0.000939	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—IL6—acquired immunodeficiency syndrome	5.77e-05	0.000937	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.75e-05	0.000933	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.68e-05	0.000921	CbGpPWpGaD
Naloxone—CREB1—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	5.65e-05	0.000917	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	5.56e-05	0.000903	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	5.56e-05	0.000902	CbGpPWpGaD
Naloxone—CREB1—Immune System—MBL2—acquired immunodeficiency syndrome	5.53e-05	0.000898	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.43e-05	0.000881	CbGpPWpGaD
Naloxone—CREB1—Adipogenesis—IL6—acquired immunodeficiency syndrome	5.37e-05	0.000871	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.32e-05	0.000864	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	5.31e-05	0.000861	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.25e-05	0.000852	CbGpPWpGaD
Naloxone—SLCO1A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.24e-05	0.00085	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.23e-05	0.000849	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.21e-05	0.000846	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.21e-05	0.000846	CbGpPWpGaD
Naloxone—TLR4—Immune System—IFNG—acquired immunodeficiency syndrome	5.21e-05	0.000845	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.1e-05	0.000827	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CCNT1—acquired immunodeficiency syndrome	5.06e-05	0.000821	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	5.05e-05	0.000819	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.04e-05	0.000818	CbGpPWpGaD
Naloxone—CREB1—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	5.03e-05	0.000817	CbGpPWpGaD
Naloxone—CREB1—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	5.03e-05	0.000817	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD4—acquired immunodeficiency syndrome	5.03e-05	0.000816	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.02e-05	0.000815	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.02e-05	0.000815	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5e-05	0.000812	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5e-05	0.000812	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.9e-05	0.000795	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.9e-05	0.000795	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	4.89e-05	0.000794	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.89e-05	0.000793	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.85e-05	0.000787	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.81e-05	0.000781	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.75e-05	0.000771	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.74e-05	0.000769	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.73e-05	0.000768	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	4.72e-05	0.000765	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.67e-05	0.000758	CbGpPWpGaD
Naloxone—CREB1—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	4.67e-05	0.000757	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.64e-05	0.000753	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL2—acquired immunodeficiency syndrome	4.63e-05	0.000751	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.59e-05	0.000745	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.57e-05	0.000742	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.54e-05	0.000737	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	4.53e-05	0.000735	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	4.53e-05	0.000734	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.53e-05	0.000734	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	4.5e-05	0.000731	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	4.49e-05	0.000729	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	4.48e-05	0.000727	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	4.47e-05	0.000726	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.46e-05	0.000724	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.46e-05	0.000724	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—IL6—acquired immunodeficiency syndrome	4.46e-05	0.000724	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.45e-05	0.000722	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.45e-05	0.000722	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.4e-05	0.000715	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.39e-05	0.000712	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.39e-05	0.000712	CbGpPWpGaD
Naloxone—CREB1—Immune System—CCR2—acquired immunodeficiency syndrome	4.34e-05	0.000704	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.3e-05	0.000697	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.3e-05	0.000697	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	4.2e-05	0.000681	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—IL6—acquired immunodeficiency syndrome	4.2e-05	0.000681	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	4.2e-05	0.000681	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	4.16e-05	0.000675	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.15e-05	0.000674	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	4.12e-05	0.000669	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	4.1e-05	0.000666	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.97e-05	0.000644	CbGpPWpGaD
Naloxone—CREB1—Immune System—IFNA1—acquired immunodeficiency syndrome	3.91e-05	0.000634	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.9e-05	0.000633	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.9e-05	0.000633	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.88e-05	0.000629	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.86e-05	0.000627	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD79A—acquired immunodeficiency syndrome	3.79e-05	0.000615	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.79e-05	0.000615	CbGpPWpGaD
Naloxone—CREB1—Disease—CXCR4—acquired immunodeficiency syndrome	3.77e-05	0.000611	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.73e-05	0.000605	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.72e-05	0.000603	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.71e-05	0.000602	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.71e-05	0.000602	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.67e-05	0.000596	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	3.65e-05	0.000593	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.63e-05	0.000589	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.63e-05	0.000589	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	3.6e-05	0.000584	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.59e-05	0.000583	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	3.51e-05	0.00057	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.51e-05	0.000569	CbGpPWpGaD
Naloxone—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	3.49e-05	0.000567	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	3.44e-05	0.000557	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.4e-05	0.000551	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.39e-05	0.000549	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.36e-05	0.000545	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.35e-05	0.000544	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.35e-05	0.000543	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.33e-05	0.000541	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.3e-05	0.000535	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.3e-05	0.000535	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.29e-05	0.000534	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.29e-05	0.000534	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.27e-05	0.00053	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.22e-05	0.000523	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.2e-05	0.00052	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	3.1e-05	0.000504	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.1e-05	0.000503	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.09e-05	0.000502	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD40LG—acquired immunodeficiency syndrome	3.09e-05	0.000502	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	3.06e-05	0.000497	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.000497	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD8A—acquired immunodeficiency syndrome	3.06e-05	0.000496	CbGpPWpGaD
Naloxone—CREB1—Immune System—CSF2—acquired immunodeficiency syndrome	3.06e-05	0.000496	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.05e-05	0.000495	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.01e-05	0.000489	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	2.99e-05	0.000485	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.97e-05	0.000483	CbGpPWpGaD
Naloxone—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	2.97e-05	0.000482	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.97e-05	0.000482	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.95e-05	0.000478	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.95e-05	0.000478	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.94e-05	0.000477	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.92e-05	0.000475	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.9e-05	0.000471	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.89e-05	0.00047	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.86e-05	0.000464	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.000455	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.8e-05	0.000454	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.000454	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.76e-05	0.000448	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.72e-05	0.000442	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—acquired immunodeficiency syndrome	2.72e-05	0.000441	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.71e-05	0.00044	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.67e-05	0.000434	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.66e-05	0.000432	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.64e-05	0.000428	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.64e-05	0.000428	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.000427	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.000427	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.6e-05	0.000422	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—acquired immunodeficiency syndrome	2.59e-05	0.00042	CbGpPWpGaD
Naloxone—CREB1—Disease—CCR5—acquired immunodeficiency syndrome	2.58e-05	0.000419	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.51e-05	0.000407	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.49e-05	0.000404	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.47e-05	0.000401	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.45e-05	0.000398	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.36e-05	0.000384	CbGpPWpGaD
Naloxone—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.31e-05	0.000374	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.31e-05	0.000374	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.31e-05	0.000374	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.29e-05	0.000372	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.29e-05	0.000371	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.26e-05	0.000367	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.07e-05	0.000336	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.03e-05	0.00033	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.01e-05	0.000326	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.000325	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.98e-05	0.000321	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.00032	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.95e-05	0.000316	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.95e-05	0.000316	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.94e-05	0.000315	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.89e-05	0.000306	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.85e-05	0.0003	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.84e-05	0.000298	CbGpPWpGaD
Naloxone—CREB1—Immune System—IFNG—acquired immunodeficiency syndrome	1.82e-05	0.000295	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.81e-05	0.000293	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.000292	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000287	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.76e-05	0.000286	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD4—acquired immunodeficiency syndrome	1.76e-05	0.000285	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.75e-05	0.000285	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.73e-05	0.00028	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.73e-05	0.00028	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.00028	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.7e-05	0.000276	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.7e-05	0.000275	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.63e-05	0.000265	CbGpPWpGaD
Naloxone—CREB1—Disease—CD4—acquired immunodeficiency syndrome	1.62e-05	0.000263	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000262	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.6e-05	0.00026	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.000256	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.55e-05	0.000251	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.48e-05	0.000241	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.46e-05	0.000237	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.44e-05	0.000233	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.38e-05	0.000223	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.34e-05	0.000217	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.31e-05	0.000213	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.31e-05	0.000212	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.29e-05	0.00021	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.25e-05	0.000202	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000198	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.18e-05	0.000192	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.14e-05	0.000185	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000169	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000169	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000169	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000168	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—acquired immunodeficiency syndrome	9.49e-06	0.000154	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.13e-06	0.000148	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.08e-06	0.000147	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—acquired immunodeficiency syndrome	8.77e-06	0.000142	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.71e-06	0.000125	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.68e-06	0.000125	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.84e-06	0.000111	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.14e-06	9.96e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	6.13e-06	9.94e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.12e-06	9.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.37e-06	8.71e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	5.34e-06	8.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.53e-06	7.36e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.02e-06	6.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.29e-06	5.34e-05	CbGpPWpGaD
